NCT04543110 - Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

November 30, 2024

Conditions

Bladder Cancer

Interventions

DRUG

Durvalumab

Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma

RADIATION

Immune Modulating Radiation

Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma

Trial Locations (4)

RECRUITING

Cross Cancer Institute, Edmonton

RECRUITING

Juravinski Cancer Centre, Hamilton

RECRUITING

London Health Sciences Centre, London

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa